INVERSINE Drug Patent Profile
✉ Email this page to a colleague
When do Inversine patents expire, and when can generic versions of Inversine launch?
Inversine is a drug marketed by Targacept and is included in one NDA.
The generic ingredient in INVERSINE is mecamylamine hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mecamylamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inversine
A generic version of INVERSINE was approved as mecamylamine hydrochloride by LGM PHARMA on March 19th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INVERSINE?
- What are the global sales for INVERSINE?
- What is Average Wholesale Price for INVERSINE?
Summary for INVERSINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 6 |
| Patent Applications: | 482 |
| DailyMed Link: | INVERSINE at DailyMed |
Recent Clinical Trials for INVERSINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Alliance for Research on Schizophrenia and Depression | Phase 3 |
| Yale University | Phase 3 |
| Ohio State University | Phase 1 |
US Patents and Regulatory Information for INVERSINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targacept | INVERSINE | mecamylamine hydrochloride | TABLET;ORAL | 010251-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
